Abrogation of chronic rejection in rat model system involves modulation of the mTORC1 and mTORC2 pathways

Transplantation

Volumn 96, Issue 9, 2013, Pages 782-790

  Zhang, Li ^a,b,c   You, Junping ^b,c   Sidhu, Jitinderpal ^c   Tejpal, Neelam ^b,c   Ganachari, Malathesha ^c   Skelton, T Spencer ^b,c   Kloc, Malgorzata ^b,c   Li, Xian C ^b,c   Ghobrial, Rafik M ^b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Actin cytoskeleton; Chronic rejection; mTOR; Rac1; Transplantation

Indexed keywords

ALLOCHIMERIC PEPTIDE; CYCLOSPORIN A; DEPTOR PROTEIN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PEPTIDE DERIVATIVE; PROTEIN SIN1; RAC1 PROTEIN; RAPTOR PROTEIN; RICTOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC GRAFT REJECTION; CHRONIC GRAFT REJECTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GRAFT RECIPIENT; HEART TRANSPLANTATION; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARRIER PROTEINS; CHRONIC DISEASE; CYCLOSPORINE; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MULTIPROTEIN COMPLEXES; PHOSPHOPROTEINS; RAC1 GTP-BINDING PROTEIN; RATS; RATS, INBRED ACI; RATS, WISTAR; SIGNAL TRANSDUCTION; SIROLIMUS; T-LYMPHOCYTES; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84888136864     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182a2034f     Document Type: Article

References (44)

1. Trivedi HL. Immunobiology of rejection and adaptation. Transplant Proc 2007; 39: 647
2. Butcher GW, Howard JC. Genetic control of transplant rejection. Transplantation 1982; 34: 161
3. Dunn DL. Problems related to immunosuppression. Infection and malignancy occurring after solid organ transplantation. Critical Care Clinics 1990; 6: 955
4. Colovai AI, Renna-Molajoni E, Cortesini R, et al. New approaches to specific immunomodulation in transplantation. Int Rev Immunol 1996; 13: 161
5. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14: 88
6. Ghobrial RM, Hamashima T, Wang M, et al. Induction of transplantation tolerance by chimeric donor/recipient class I RT1.Aa molecules. Transplantation 1996; 62: 1002
7. Semiletova N, Shen X-D, Fishbein MC, et al. Posttransplant administration of allochimeric major histocompatibility complex class-Imolecules induces true transplantation tolerance. Transplantation 2003; 75: 550
8. Semiletova NV, Shen X-D, Baibakov B, et al. Inhibition of chronic rejection by antibody induced vascular accommodation in fully allogeneic heart allografts. Transplantation 2005; 80: 1535
9. Singer JS, Mhoyan A, Fishbein MC, et al. Allochimeric class I MHC molecules prevent chronic rejection and attenuate alloantibody responses. Transplantation 2001; 72: 1408
10. Skelton T, Cordero AM, Nelles NJ, et al. Allochimeric MHC Iconditioned T cells attenuate chronic rejection in rat cardiac model system. J Clin Cell Immunol 2011; 2: 108
11. Lisik W, Tejpal N, Gong Y, et al. Down regulation of genes involved in T cell polarity and motility during the induction of heart allograft tolerance by allochimeric MHC I. PLoS One 2009; 4: E8020
12. Skelton TS, Tejpal N, Gong Y, et al. Allochimeric molecules and mechanisms in abrogation of cardiac allograft rejection. J Heart Lung Transplant 2012; 31: 73
13. Skelton TS, Tejpal N, Gong Y, et al. Downregulation of RhoA and changes in T cell cytoskeleton correlate with the abrogation of allograft rejection. Transpl Immunol 2010; 23: 185
14. Lisik W, Gong Y, Tejpal N, et al. Intragraft gene expression profile associated with the induction of tolerance by allochimeric MHC I in the rat heart transplantation model. Genesis 2010; 48: 8
15. Liu D, Shen XD, Zhai Y, et al. Intragraft selection of the T cell receptor repertoire by class I MHC sequences in tolerant recipients. PLoS One 2009; 4: E6076
16. Zhang L, Kloc M, Tejpal N, et al. ROCK1 inhibitor abrogates chronic rejection in rat cardiac model system. Open J Organ Transpl Surg 2012; 2: 46
17. Wheelera AP, Ridley AJ. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res 2004; 301: 43
18. Delaguillaumie A, Lagaudrière-Gesbert C, Popoff MR, et al. Pases link cytoskeletal rearrangements and activation processes induced via the tetraspanin CD82 in T lymphocytes. J. Cell Sci 2002; 115: 433
19. Nijhara R, van Hennik PB, Gignac ML, et al. Rac1 mediates collapse of microvilli on chemokine-activated T lymphocytes. J. Immunol 2004; 173: 4985
20. Lee JH, Katakai T, Hara T, et al. Roles of p-ERM and Rho-ROCK signaling in lymphocyte polarity and uropod formation. J Cell Biol 2004; 167: 327
21. Pernis AB Rho GTPase-mediated pathways in mature CD4+ T cells. Autoimmun Rev 2009; 8: 199
22. Xu Y, Li J, Ferguson GD, et al. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood. 2009; 114: 338
23. Gulhati P, Bowen KA, Liu J, et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 2011; 71: 3246
24. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122
25. Liu L, Luo Y, Chen L, et al. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J Biol Chem 2010; 285: 38362
26. Gangoiti P, Arana L, Ouro A, et al. (2011). Activation of mTOR and RhoA is a major mechanism by which ceramide 1-phosphate stimulates macrophage proliferation. Cell Signal 2011; 23: 27
27. Wullschleger S, Loewith R, Hall M. TOR signaling in growth and metabolism. Cell 2006; 124: 471
28. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9: 324
29. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007; 12: 487
30. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159
31. McMahon G, Weir MR, Li XC, et al. The evolving role of mTOR inhibition in transplantation tolerance. J Am Soc Nephrol 2011; 22: 408
32. Thedieck K, Polak P, Kim ML, et al. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One 2007; 11: E1217
33. Oshiro N, Takahashi R, Yoshino K, et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 2007; 282: 20329
34. Lazorchak AS, Liu D, Facchinetti V, et al. Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells. Mol Cell 2010; 39: 433
35. Pearce LR, Huang X, Boudeau J, et al. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 2007; 405: 513
36. Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor whose frequent overexpression in multiple myeloma cells promotes their survival. Cell 2009; 137: 873
37. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 2011; 71: 3246-56
38. Jacinto E, Loewith R, Schmidt A, Lin S, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature Cell Biol 2004; 6: 1122-28
39. Liu L, Luo Y, Chen L, Shen T, Xu B, Chen W, Zhou H, Han X, Huang S. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J. Biol. Chem 2010; 285: 38362-73
40. Gangoiti P, Arana L, Ouro A, Granado MH, Trueba M, Gómez- Muñoz A. Activation of mTOR and RhoA is a major mechanism by which Ceramide 1-phosphate stimulates macrophage proliferation. Cell Signal 2011; 23: 27-34
41. Schuldt A. Cell growth: RAC1 sizes up mTOR. Nat Rev Mol Cell Biol 2011; 12: 343
42. Saci A, Cantley LC, Carpenter CL. Rac1 Regulates the Activity of mTORC1 and mTORC2 and Controls Cellular Size. Mol. Cell 2011; 42: 50-61
43. Bridgesa D, Maa J-T, Parka S, Inokia K, Weismana LS, Saltiela AR. Phosphatidylinositol 3,5-bisphosphate plays a role in the activation and subcellular localization of mechanistic target of rapamycin 1. Mol. Biol. Cell 2012; 23: 2955-2962
44. Partovian C, Ju R, Zhuang ZW, Martin K, Simons M. Syndecan-4 regulates subcellular localization of mTOR complex2 and Akt activation in a PKCa-dependent manner in endothelial cells. Mol Cell 2008; 32: 140-149